Fig. 7
From: EGR1 suppresses HCC growth and aerobic glycolysis by transcriptionally downregulating PFKL
AAV-EGR1 inhibited HCC in a DEN/CCL4 driven mouse model of HCC in vivo and inhibited human hepatoma organoid growth in vitro. A DEN/CCl4 induced mice with HCC were treated with AAV-EGR1 in vivo to examine the impact of AAV-EGR1 on tumor development. B The anti-tumor effect of AAV-EGR1 was observed in comparison with AAV-control through typical images of tumor-bearing mice livers; the number of mice in each treatment group was n = 6. C Tumor nodules were quantified and tumor sizes were measured upon liver harvest. D The serum of mice was tested for the levels of ALT and AST. E The staining of HE, EGR1, PFKL, and Ki67 in mice livers was presented. F Representative images of human hepatoma organoid demonstrated the anti-tumor effect of AAV-EGR1 in comparison with AAV-control. *P < 0.05, **P < 0.01, ***P < 0.001